Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

@article{Hannemann2006MolecularSO,
  title={Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy},
  author={Juliane Hannemann and Petra Kristel and H Van Tinteren and Marijke Bontenbal and Q G van Hoesel and Wim M Smit and Marianne A. Nooij and Emile E. Voest and Elsken van der Wall and P. Hupperets and Elisabeth G. E. de Vries and Sjoerd Rodenhuis and Marc J. van de Vijver},
  journal={British Journal of Cancer},
  year={2006},
  volume={95},
  pages={1334 - 1341}
}
Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by immunohistochemistry in tumours of patients who took part in a randomised study of adjuvant high-dose chemotherapy in breast cancer. In addition, the topoisomerase IIα (TOP2A) amplification status was determined by fluorescence in situ hybridisation… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2008
VIEW 19 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Repeated observation of breast tumor subtypes in independent gene expression data sets.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer

S Rodenhuis, M Bontenbal, +9 authors EG de Vries
  • Ann Oncol 17:
  • 2006
VIEW 3 EXCERPTS

Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial

MF Press, L Bernstein, +11 authors DJ Slamon
  • 2005
VIEW 1 EXCERPT

Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
VIEW 3 EXCERPTS